Replies to post #198882 on Biotech Values

[DewDiligence]

Re: OCRX oral formulation of OCR-002

Today’s PR puts to rest the notion that OCRX is seeking a qD oral formulation:

“We are focused on developing an oral formulation of OCR-002 that is safe, well tolerated and effective with twice-daily dosing.

We believe a product designed with these characteristics will play an important role in managing patients with advanced cirrhosis and preventing acute episodes of hepatic encephalopathy, which in 2013 contributed to over 180,000 hospitalizations in the U.S.”

Although we now know the additional formulation optimization OCRX is conducting has nothing to do with qD dosing, we still don’t know what it does have to do with:

The Company plans to conduct additional Phase 1 testing after further formulation optimization.

Essentially the same statement as in OCRX’s PR from 11/16/15 (#msg-118538497).